Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.

  title={Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.},
  author={Handan He and Phi Tran and Hequn Yin and Harold C. Smith and Yannick Batard and Lai Mun Wang and Heidi J. Einolf and Helen Gu and James B. Mangold and Volker G. Fischer and Dan Howard},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  volume={37 3},
The absorption, metabolism, and excretion of (1-[[3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine (vildagliptin), an orally active and highly selective dipeptidyl peptidase 4 inhibitor developed for the treatment of type 2 diabetes, were evaluated in four healthy male subjects after a single p.o. 100-mg dose of [(14)C]vildagliptin. Serial blood and complete urine and feces were collected for 168 h postdose. Vildagliptin was rapidly absorbed, and peak plasma concentrations were… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
43 Citations
19 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 43 extracted citations


Publications referenced by this paper.
Showing 1-10 of 19 references

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of DPP-4, in healthy subjects; results from two randomized double-blind, placebocontrolled studies with single oral dose

  • GA Herman, C Stevens, +7 authors W Tanaka
  • Clin Pharmacol Ther 78:675–688
  • 2005
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…